We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology Drugs


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "FORMA Therapeutics Announces Collaboration with Boehringer Ingelheim to Develop Novel Oncology Drugs"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Under the terms of the collaboration, FORMA will receive a total of $65 million in up-front payments and research funding to screen for and optimize compounds against multiple oncology targets over the next four years.   FORMA could be eligible for up to $750 million in pre-commercial milestones for programs resulting from the collaboration.  Further financial details were not disclosed.

“Many of the ‘un-druggable’ and/or novel targets in oncology involve protein-protein interactions,” said Kenneth Bair, Ph.D., Senior Vice President and Head of Research and Development of FORMA. “We are really excited about tackling these essential targets with Boehringer Ingelheim.”

“This creative deal provides Boehringer Ingelheim with access to our drug discovery capabilities in cancer but also offers FORMA and our shareholders several opportunities to realize early return through assets developed under this collaboration,” commented Steven Tregay, Ph.D., Chief Executive Officer of FORMA.

Advertisement